Research Compendium: Schizophrenia Study Design and Conduct Date Published: Oct 13, 2021 Article Signant’s clinical advisory leaders regularly conduct and participate in collaborative research to advance the science of drug development. The articles and posters below explore a range of topics with respect to Schizophrenia clinical trial design and conduct, and feature many of Signant’s renowned CNS subject matter experts. The Impact of Aberrant Data Variability on Drug–Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical TrialDOWNLOAD Site ratings versus site-independent ratings of PANSS interviews in a schizophrenia studyDOWNLOAD The Effects of Erratic Ratings on Placebo Response and Signal Detection in the Roche Bitopertin Phase 3 Negative Symptom Studies—A Post Hoc AnalysisDOWNLOAD Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo?DOWNLOAD Audio-digital recordings to assess ratings reliability in clinical trials of schizophreniaDOWNLOAD Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus StatementsDOWNLOAD Share: LinkedInTweet